Homology appoints Albert Seymour President; Tzianabos remains CEO, Seymour gets new equity grant

Q32 Bio Inc.

Albert Seymour promoted to President effective April 21, 2022, while remaining Chief Scientific Officer.
Arthur Tzianabos resigns as President but continues as Chief Executive Officer of Homology.
Seymour's base salary increased to $545,000; target annual bonus set at 50% of base salary.
Seymour receives option to purchase 60,000 shares at $1.78, vesting over 48 months.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Arthur O. Tzianabos

President

QTTB · Q32 Bio Inc.

Effective: 2022-04-21
Successor: Albert Seymour
Filed: April 21, 2022, 7:59 PM ET

Arthur O. Tzianabos, Ph.D., in connection with Dr. Seymour’s promotion, notified the Company on April 19, 2022 of his resignation as President, effective as of April 21, 2022.

Role change

Albert Seymour

President

QTTB · Q32 Bio Inc.

Effective: 2022-04-21
Filed: April 21, 2022, 7:59 PM ET

On April 19, 2022, the Board of Directors of Homology Medicines, Inc. (the “Company”) appointed Albert Seymour, Ph.D., the Company’s current Chief Scientific Officer, to serve as the Company’s President, effective as of April 21, 2022, in addition to his role as the Company’s Chief Scientific Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Arthur O. Tzianabos resigned as President at Q32 Bio Inc..

Action: resigned
Role: President

Exact text from the filing

Arthur O. Tzianabos, Ph.D., in connection with Dr. Seymour’s promotion, notified the Company on April 19, 2022 of his resignation as President, effective as of April 21, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Albert Seymour was appointed as President at Q32 Bio Inc..

Action: appointed
Role: President

Exact text from the filing

On April 19, 2022, the Board of Directors of Homology Medicines, Inc. (the “Company”) appointed Albert Seymour, Ph.D., the Company’s current Chief Scientific Officer, to serve as the Company’s President, effective as of April 21, 2022, in addition to his role as the Company’s Chief Scientific Officer.

View on SEC.gov

Q32 Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-113203

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.